The PCSK9 Inhibitors Market is rapidly becoming a game changer in lipid therapy, offering a highly effective option for lowering LDL cholesterol levels, particularly in patients who are statin-intolerant or require more aggressive lipid-lowering interventions. With cardiovascular disease still topping global mortality charts, this innovative class of drugs is set to redefine the future...